Antiangiogenic agents, together with inhibitors of the mechanistic target of rapamycin (mTOR) pathway, that are affected by activating mutations in ccRCC, and immune checkpoint inhibitors are therefore used in the clinical management of advanced and metastatic ccRCC.19, 20. This evidence concerns the gene MTOR and nonpapillary renal cell carcinoma.